Evidence for a Cystic Fibrosis Enteropathy
Open Access
- 20 October 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (10) , e0138062
Abstract
Previous studies have suggested the existence of enteropathy in cystic fibrosis (CF), which may contribute to intestinal function impairment, a poor nutritional status and decline in lung function. This study evaluated enterocyte damage and intestinal inflammation in CF and studied its associations with nutritional status, CF-related morbidities such as impaired lung function and diabetes, and medication use. Sixty-eight CF patients and 107 controls were studied. Levels of serum intestinal-fatty acid binding protein (I-FABP), a specific marker for enterocyte damage, were retrospectively determined. The faecal intestinal inflammation marker calprotectin was prospectively studied. Nutritional status, lung function (FEV1), exocrine pancreatic insufficiency (EPI), CF-related diabetes (CFRD) and use of proton pump inhibitors (PPI) were obtained from the medical charts. Serum I-FABP levels were elevated in CF patients as compared with controls (p<0.001), and correlated negatively with FEV1 predicted value in children (r-.734, p<0.05). Faecal calprotectin level was elevated in 93% of CF patients, and correlated negatively with FEV1 predicted value in adults (r-.484, p<0.05). No correlation was found between calprotectin levels in faeces and sputum. Faecal calprotectin level was significantly associated with the presence of CFRD, EPI, and PPI use. This study demonstrated enterocyte damage and intestinal inflammation in CF patients, and provides evidence for an inverse correlation between enteropathy and lung function. The presented associations of enteropathy with important CF-related morbidities further emphasize the clinical relevance.Keywords
This publication has 61 references indexed in Scilit:
- Serum I‐FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodiesAlimentary Pharmacology & Therapeutics, 2013
- Serial Analysis of the Gut and Respiratory Microbiome in Cystic Fibrosis in Infancy: Interaction between Intestinal and Respiratory Tracts and Impact of Nutritional ExposuresmBio, 2012
- Impaired Mucosal Barrier Function in the Small Intestine of the Cystic Fibrosis MouseJournal of Pediatric Gastroenterology and Nutrition, 2011
- Epidermal Growth Factor Improves SurvivaL and Prevents Intestinal Injury in a Murine Model of Pseudomonas aeruginosa PneumoniaShock, 2011
- Small intestine bacterial overgrowth does not correspond to intestinal inflammation in cystic fibrosisScandinavian Journal of Clinical and Laboratory Investigation, 2010
- Pass the bicarb: the importance of HCO3– for mucin releaseJournal of Clinical Investigation, 2009
- Sputum Proteomics in Inflammatory and Suppurative Respiratory DiseasesAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Fecal calprotectin and elastase 1 determinations in patients with pancreatic diseases: a possible link between pancreatic insufficiency and intestinal inflammationJournal of Gastroenterology, 2007
- Bacterial Overgrowth in the Cystic Fibrosis Transmembrane Conductance Regulator Null Mouse Small IntestineInfection and Immunity, 2004
- Innate Lung Defenses and CompromisedPseudomonas aeruginosaClearance in the Malnourished Mouse Model of Respiratory Infections in Cystic FibrosisInfection and Immunity, 2000